Smoking may speed MS disability in people without a gene

Credibility

Interest

Share:2 min read

Key Takeaway

Smoking at MS diagnosis raises the risk of faster disability for people who do NOT carry a common immune-system gene called HLA-DRB1*15.

What They Found

Researchers followed over 6,800 people with MS for up to 15 years to see how smoking and a gene called HLA-DRB1*15 affect disability over time. They found that people who smoked when they were diagnosed had a higher chance of getting worse on standard disability tests if they did NOT carry the HLA-DRB1*15 gene. For people who do carry the HLA-DRB1*15 gene, smoking did not show a clear link to faster disability in this study. The study used common disability milestones (like needing more help walking) to measure change, and smoked-at-diagnosis was tied to reaching those milestones sooner in non-carriers. Overall, the results suggest that the effect of smoking on MS progression can depend on a person’s immune-system genes.

Who Should Care and Why

People with MS and their caregivers should care because this study suggests that quitting smoking could matter more for some people depending on their genes. Think of the gene like a lock and smoking like a key — for some locks the key speeds things up, for others it does not, so knowing which lock you have can help guide choices. Patients who smoke might choose to prioritize quitting because smoking is already linked to other health problems and may speed disability for many. Caregivers and doctors can use this information to have clearer talks about quitting and monitoring symptoms more closely after diagnosis. Even if you don’t know your gene status, avoiding smoking is a low-risk step that may help keep you healthier longer.

Important Considerations

The study does not prove smoking causes faster disability for every person; it shows an association that was stronger in people without HLA-DRB1*15. The gene information was grouped (carriers vs non-carriers) and not every possible genetic or lifestyle factor was measured, so results aren’t the final word for every individual. If you want personalized advice, ask your MS care team — they can explain genetic testing options and help with smoking cessation support.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Genetics MS Progression Early Research

Article Topics:

Multiple sclerosisdisability progressiongene–environment interactionhuman leukocyte antigensmoking

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News